Clinical trials: Low Grade
Malignant Glioma
Low Dose Naltrexone for Glioma Patients
To compare the effects of low dose naltrexone (LDN) versus placebo on quality of life in high grade glioma patients undergoing standard chemoradiation
- Trial name
- NCT01303835
- Testing
- LDN
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- Katy Peters
Liver Disease
Oral Hepatitis C Treatment for Indolent Lymphoma (OPTImaL) Study
There still remains the question if hepatitis C eradication with all oral therapy will lead to a regression or cure of the low grade lymphoma.
- Trial name
- Optimal (NCT02717949)
- Testing
- sofosbuvir/ledipasvir, sofosbuvir, Ribavirin
- Where
- 3 sites in United States
- Volunteers
- 1 people
- Sponsor
- University of Texas Southwestern Medical Center
Bladder Cancer, Urothelial Carcinoma
A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer
This Phase 3, single-arm, multicenter study was designed to evaluate the efficacy and safety of UGN-103, a novel formulation of UGN-102, instilled in the urinary bladder of patients with recurrent low-grade intermediate-risk…
- Conditions
- Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder
- Trial name
- UTOPIA (NCT06331299)
- Testing
- UGN-103
- Where
- 48 sites in United States, Bulgaria and 5 more
- Volunteers
- 99 people
- Sponsor
- UroGen Pharma Ltd.
Cancer
Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers
This was a Phase II, open-label, non-randomized, multi-center study of oral dabrafenib in combination with oral trametinib in subjects with rare cancers harboring the BRAF V600E mutation including anaplastic thyroid cancer (ATC)…
- Trial name
- NCT02034110
- Testing
- Dabrafenib, Trametinib
- Where
- 41 sites in United States, Austria and 12 more
- Volunteers
- 206 people
- Sponsor
- Novartis Pharmaceuticals
Ovarian Cancer
Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer
This is a double blind, randomized, placebo-controlled, 2-arm, Phase 2 trial investigating the efficacy and safety of combination therapy of pimasertib plus SAR245409 and pimasertib placebo administered once per day compared to…
- Trial name
- NCT01936363
- Testing
- Pimasertib once daily, SAR245409, Pimasertib twice daily
- Where
- 34 sites in United States, Australia and 5 more
- Volunteers
- 65 people
- Sponsor
- EMD Serono
Low Grade Glioma
Ovarian Aging in Low Grade Glioma (LGG) Treated With Temozolomide
The purpose of this study is to look at how a chemotherapy treatment (Temozolomide, also called Temodar) affects the process of ovarian aging which is measured by a decline in ovarian follicle count, in patients with Low Grade…
- Trial name
- OVA-LGG (NCT01452854)
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of California, San Francisco
Headaches Associated With Subarachnoid Hemorrhage (SAH)
Randomized Trial for Pain Management in Low-grade Subarachnoid Hemorrhage
Headaches associated with subarachnoid hemorrhage (SAH) cause severe pain. Headache management is complex, requiring a balance between pain control and preservation of neurological assessment.
- Trial name
- NCT01851720
- Testing
- Low dose fentanyl PCA, Standard IV fentanyl bolus
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Johns Hopkins University
Brain and Central Nervous System Tumors
Temozolomide and Radiation Therapy in Treating Patients With Gliomas
RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00114140
- Testing
- Temozolomide, Radiation therapy
- Where
- 47 sites in United States, Canada
- Volunteers
- 136 people
- Sponsor
- Radiation Therapy Oncology Group
Lymphoma, Non-Hodgkin
Study of Safety and Efficacy of a Sequential Regimen Consisting of Three Cycles of Fludarabine Followed by Tositumomab and Iodine I 131 Tositumomab
This is a single-arm, single institution, phase II study of fludarabine monophosphate followed by Iodine I 131 Tositumomab for patients with previously untreated, advanced-stage (stage III or IV) low-grade, transformed low-grade…
- Trial name
- NCT00933335
- Testing
- Tositumomab and Iodine I 131 Tositumomab
- Volunteers
- 38 people
- Sponsor
- GlaxoSmithKline
Lymphoma, Non-Hodgkins
Ofatumumab and Bortezomib for Patients With Low-grade B-cell Non-hodgkin Lymphoma That Relapse After Rituximab
The purpose of this study is to: Investigate the Overall Response Rate (ORR) of the combination of ofatumumab and bortezomib in patients with low-grade B-cell non-Hodgkin lymphoma (LG-NHL) that relapse beyond 6 months of a…
- Trial name
- NCT01119794
- Testing
- Ofatumumab and Bortezomib
- Where
- 3 sites in United States
- Volunteers
- 10 people
- Sponsor
- Brown University
Gastrointestinal Neoplasm
Debulking and Chemotherapy With or Without Intraperitoneal Chemotherapy to Treat Peritoneal Carcinomatosis
This study will determine which of the two following treatment regimens provides greater benefit to patients with peritoneal carcinomatosis (gastrointestinal cancer that has spread throughout the abdomen): Surgical removal of…
- Trial name
- NCT00052962
- Testing
- Cytoreductive surgery, Continuous hyperthermic peritoneal perfusion (HIPEC/CHPP)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Brain Tumors
A Trial of Poly-ICLC in the Management of Recurrent Pediatric Low Grade Gliomas
This study is for patients up to 21 years of age who have a tumor called a low grade glioma of the central nervous system (brain and spinal cord). The tumor has grown despite attempts to control it with chemotherapy or radiation.
- Trial name
- Poly-ICLC (NCT01188096)
- Testing
- Poly ICLC
- Where
- 2 sites in United States
- Volunteers
- 23 people
- Sponsor
- Wake Forest University Health Sciences
Lymphoma, Non-Hodgkin
A Randomized Study of Iodine-131 Anti-b1 Antibody Versus Anti-b1 Antibody in Chemotherapy-relapsed/Refractory Low-grade or Transformed Low-grade Non-Hodgkin's Lymphoma (NHL)
Subjects were randomized to receive either tositumomab (Anti-B1 Antibody) and iodine I 131 tositumomab (Arm A) or unlabeled tositumomab (Arm B).
- Trial name
- NCT01573000
- Testing
- Iodine-131 Anti-B1 Antibody Versus Anti-B1 Antibody in Chemotherapy-Relapsed/Refractory Low-Grade or Transformed Low-Grade Non-Hodgkin's Lymphoma (NHL)
- Volunteers
- 78 people
- Sponsor
- GlaxoSmithKline
Non-Hodgkin Lymphoma, Mycosis Fungoides
CPG 7909 + Local Radiotherapy in Recurrent Low-Grade Lymphomas
Brief summary TBD
- Trial name
- NCT00185965
- Testing
- CPG 7909
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Ronald Levy
Barrett Esophagus, Esophageal Carcinoma
Ursodiol in Treating Patients With Barrett Esophagus and Low-Grade Dysplasia
This pilot phase II trial studies how well ursodiol works in treating patients with Barrett esophagus or cells that look abnormal under a microscope but are not cancer (low-grade dysplasia).
- Trial name
- NCT01097304
- Testing
- Ursodiol, Laboratory Biomarker Analysis
- Where
- 4 sites in United States
- Volunteers
- 36 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia, Lymphoma
Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Cancer
RATIONALE: Pentostatin may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cyclophosphamide and mitoxantrone, work in different ways to stop the growth…
- Trial name
- NCT00546377
- Testing
- filgrastim, pegfilgrastim, rituximab
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Indolent Non-Hodgkin's Lymphoma, Follicular Lymphoma
Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymphoma
The primary objectives of this study is to evaluate the safety and efficacy of idelalisib (GS-1101, CAL-101) in participants with previously treated indolent non-Hodgkin lymphoma (iNHL).
- Conditions
- Indolent Non-Hodgkin's Lymphoma, Follicular Lymphoma, Small Lymphocytic Lymphoma, Marginal Zone Lymphoma
- Trial name
- NCT01306643
- Testing
- Idelalisib
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Gilead Sciences
Glioma
Safety Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Tumors of the Brain
The prodrug, 5-Aminolevulinic acid (ALA), has been shown to lead to intracellular accumulation of fluorescent porphyrins in high grade malignant gliomas in the brain.
- Trial name
- ALA (NCT01116661)
- Testing
- 5-Aminolevuline Acid (ALA)
- Where
- United States
- Volunteers
- 199 people
- Sponsor
- University of California, San Francisco
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
This phase II trial studies how well giving fludarabine phosphate, melphalan, and low-dose total-body irradiation (TBI) followed by donor peripheral blood stem cell transplant (PBSCT) works in treating patients with hematologic…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Trial name
- NCT01529827
- Testing
- fludarabine phosphate, melphalan, total-body irradiation
- Where
- United States
- Volunteers
- 94 people
- Sponsor
- Roswell Park Cancer Institute
Follicular Low Grade Non-Hodgkin's Lymphoma
Study of Intratumoral G100 With Or Without Pembrolizumab or Rituximab In Participants With Follicular Non-Hodgkin's Lymphoma (MK-3475-174/IMDZ-G142)
This is a Phase 1/2 open label trial of G100 in participants with low grade Non-Hodgkin's Lymphoma (NHL). G100 is composed of glucopranosyl lipid A in a stable emulsion and is a potent TLR4 (toll-like receptor-4) agonist.
- Trial name
- NCT02501473
- Testing
- G100, Pembrolizumab, Rituximab
- Volunteers
- 52 people
- Sponsor
- Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)